Pliant Therapeutics, Inc. announced the discontinuation of the development of bexotegrast for idiopathic pulmonary fibrosis $(IPF.UK)$ following a review of data from the BEACON-IPF Phase 2b/3 clinical trial. The decision was based on a recommendation from the trial's Data Safety Monitoring Board and an outside expert panel due to an imbalance in IPF-related adverse events. Despite this, Pliant continues to advance its clinical oncology program, with the ongoing Phase 1 trial of PLN-101095 in patients with solid tumors resistant to immune checkpoint inhibitors. Interim results have shown that PLN-101095 was generally well tolerated. The trial is currently enrolling the last of five planned dose cohorts. Additionally, Pliant supports early-stage programs through its proprietary platform, which includes a library of integrin binding molecules and advanced screening and live human tissue assays, aimed at broadening the applicability across various disease areas.